News

EMulate Therapeutics® Reaches Patent Milestone

Newest Device Patent Raises Total to 35 Patents with More in the Pipeline

SEATTLE (PRWEB) JULY 09, 2019

EMulate Therapeutics, Inc., a clinical-stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, announced it received notice from the Australian Patent Office (now, IP Australia) granting a patent for the use of the company’s therapeutic device for administering therapy, such as cancer therapy. The patent issued in May 2019.

Chris Rivera, EMulate Therapeutics President and Chief Executive Officer, made the announcement stating, “This notice of our 35th patent issuance is an important milestone for the company. Our research and legal teams have worked diligently over the years to develop and protect our unique medical device and cognate intellectual property in the United States as well as in several other territories globally. But most importantly, it is further evidence of our efforts to protect the technology we expect to use to provide treatment for a number of forms of cancers and other serious diseases in children and adults.”

EMulate Therapeutics’ ulRFE® Voyager system is currently in clinical trials in patients diagnosed with glioblastoma (GBM). The company recently announced it has received notice that the US Food and Drug Administration (FDA) accepted for filing the EMulate Therapeutics application for Humanitarian Device Exemption (HDE) for its Hælo™ Pediatric system. The FDA granted a Humanitarian Use Device (HUD) designation for the Hælo Pediatric system in March 2018 to treat diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), as well as other cancer indications in children.

Steven Pope, EMulate’s Corporate Secretary and Senior Vice President, General Counsel, added, “Not only has our 35th patent been granted, we have other patent applications in the pipeline for the Voyager and Hælo Pediatric systems. This patent issuance is exemplary of our ongoing, forward-looking patent strategy. The uniqueness of our technology creates a need to protect our intellectual property in the United States and in other major commercial jurisdictions.”

About EMulate Therapeutics
Headquartered in Seattle, EMulate Therapeutics is a clinical-stage therapeutic device company. EMulate has invented and patented a groundbreaking technology that utilizes precisely targeted ultra-low radio frequency energy (ulRFE®) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-sterile, non-invasive, non-thermal, non-ionizing investigational device. The company’s goal is to transform disease treatment on a global scale with ulRFE, which can potentially be applied to a wide range of medical conditions as well as to veterinary medicine and non-medical applications. EMulate’s initial focus is on the treatment of patients with brain cancer, who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Pre-clinical work is focused on exploring new applications in oncology. In addition, EMulate’s Voyager system for adults with glioblastoma is an investigational medical device in clinical development.

Media Relations Contact:
Dennis Kroft
dkroft@emulatetx.com
201-602-8354

 

Back to News